Lumasiran

(Oxlumo®)

Oxlumo®

Drug updated on 5/17/2024

Dosage FormInjection (subcutaneous; 94.5 mg/0.5 mL)
Drug ClassHAO1-directed small interfering ribonucleic acid
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Lumasiran (Oxlumo) is indicated for the treatment of primary hyperoxaluria type 1 (PH1), a condition it treats by lowering urinary oxalate levels in both pediatric and adult patients.
  • Four studies from randomized controlled trials were reviewed to gather information about this drug's safety, effectiveness, and considerations for different populations and subgroups.
  • In infants and children under six years old, lumasiran was found to be effective in reducing spot urinary oxalate: creatinine ratio by 72% at six months. This effect was maintained through month twelve with an acceptable safety profile; the most common adverse events being mild injection-site reactions.
  • For PH1 patients of all ages with advanced kidney disease including those undergoing hemodialysis, lumasiran showed substantial reductions in plasma oxalate levels while maintaining an acceptable safety profile irrespective of the severity of kidney function impairment.
  • A double-blind phase three trial involving patients aged six or older demonstrated that lumasiran resulted in a significant reduction - 65.4% - in 24-hour urinary oxalate excretion compared to placebo. It also helped many treated patients achieve urinary oxalate excretion levels no higher than 1.5 times the upper limit of the normal range, indicating its efficacy against progressive kidney failure caused by PH1.
  • The studies underline broad applicability across different patient subgroups including infants/young children as well as those with advanced kidney disease on hemodialysis; consistently showing acceptable safety profiles marked mostly by mild transient injection-site reactions, which positions Lumasiran as a significant therapeutic advancement for treating PH1 across various demographics/disease severities, pending comparisons based strictly on broader clinical data.

Product Monograph / Prescribing Information

Document TitleYearSource
Oxlumo (lumasiran) Prescribing Information.2023Alnylam Pharmaceuticals, Inc., Cambridge, MA

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.
Data not availableSubjects
F: null%
M: null%
2023Pediatric Nephrology
Lumasiran for advanced primary hyperoxaluria type 1: Phase 3 ILLUMINATE-C trial.
Data not availableSubjects
F: null%
M: null%
2023American Journal of Kidney Diseases
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children.
Data not availableSubjects
F: null%
M: null%
2022Genetics in Medicine
Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1.
Data not availableSubjects
F: null%
M: null%
2021The New England Journal of Medicine

Sex Distribution:

No Data

Year:

2023

Source:American Journal of Kidney Diseases


Sex Distribution:

No Data

Year:

2021

Source:The New England Journal of Medicine

Clinical Practice Guidelines